Metastatic Prostate Cancer Pipeline

DelveInsight’s, “Metastatic Prostate Cancer Pipeline Insight, 2026” report provides comprehensive insights about 80+ companies and 85+ pipeline drugs in Metastatic Prostate Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest Metastatic Prostate Cancer Pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Geography Covered

• Global coverage

Metastatic Prostate Cancer Understanding

Metastatic Prostate Cancer Overview

Metastatic prostate cancer (MPC) is an advanced form of Prostate Cancer in which malignant cells spread from the prostate gland to distant organs, most frequently the bones, lymph nodes, liver, and lungs. It represents stage IV disease and is often categorized into stage IVA (spread to nearby tissues or lymph nodes) and stage IVB (spread to distant organs). Initially, many patients develop metastatic hormone-sensitive prostate cancer (mHSPC), which responds to androgen deprivation therapy (ADT). Over time, the disease may progress to metastatic castration-resistant prostate cancer (mCRPC) despite low testosterone levels, making it more aggressive and difficult to treat. Bone metastases occur in more than 70% of patients, while visceral metastases are seen in fewer than 30%. Survival varies depending on disease burden, reaching about 92 months in low-volume disease but dropping to roughly 55 months in high-volume cases.

Diagnosis of metastatic prostate cancer (MPC) relies on a combination of prostate-specific antigen (PSA) monitoring, imaging techniques, and biopsy confirmation once the disease spreads beyond the prostate to organs such as bones or lymph nodes. Elevated PSA levels often above 20 ng/mL or a high Gleason score (≥8) typically prompt further investigation. Conventional imaging methods like bone scans are commonly used to detect osteoblastic bone metastases, which occur in the majority of metastatic cases, 
while CT or MRI helps evaluate lymph nodes and soft tissues. 

However, these traditional approaches may miss small or early metastatic lesions. Advanced molecular imaging techniques, particularly PSMA-PET/CT, offer significantly higher sensitivity and accuracy for detecting metastatic sites even at very low PSA levels. Other modalities such as choline-PET or fluciclovine-PET can help identify biochemical recurrence and guide treatment decisions. The diagnostic workflow generally begins with PSA monitoring, followed by multiparametric MRI to localize suspicious areas for targeted biopsy. In high-risk patients, PSMA-PET imaging is increasingly preferred for staging because it improves detection rates and reduces false-negative findings.

Treatment of metastatic prostate cancer (MPC) has increasingly shifted toward intensified systemic therapy strategies recommended by major guidelines from National Comprehensive Cancer Network, American Society of Clinical Oncology, and European Association of Urology. Androgen deprivation therapy (ADT) remains the backbone of treatment and is typically combined with other agents to improve survival outcomes. In metastatic hormone-sensitive prostate cancer (mHSPC), ADT is commonly paired with androgen receptor pathway inhibitors such as Abiraterone, Enzalutamide, Apalutamide, or Darolutamide, with chemotherapy like Docetaxel added in high-risk or high-volume disease as part of doublet or triplet regimens. For metastatic castration-resistant prostate cancer (mCRPC), ADT is continued while additional treatments such as chemotherapy (docetaxel followed by Cabazitaxel), targeted therapy, or radioligand therapy are introduced. Patients with homologous recombination repair mutations, particularly BRCA1/2, may benefit from PARP inhibitors like Olaparib. Because optimal treatment sequencing is still evolving, current guidelines emphasize genomic testing, prior therapy exposure, and multidisciplinary decision-making to personalize treatment strategies and improve outcomes. 

"Metastatic Prostate Cancer Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Metastatic Prostate Cancer pipeline landscape is provided which includes the disease overview and Metastatic Prostate Cancer treatment guidelines. The assessment part of the report embraces, in depth Metastatic Prostate Cancer commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Metastatic Prostate Cancer Report Highlights

The Metastatic Prostate Cancer Companies and academics are working to assess challenges and seek opportunities that could influence Metastatic Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve Metastatic Prostate Cancer.

Metastatic Prostate Cancer Emerging Drugs Analysis

This segment of the Metastatic Prostate Cancer report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Metastatic Prostate Cancer Emerging Drugs

TLX591: Telix Pharmaceuticals

TLX591 is an investigational radio antibody-drug conjugate (rADC) being developed for the treatment of metastatic castration-resistant Prostate Cancer (mCRPC). The therapy consists of a highly specific PSMA-targeting monoclonal antibody linked through a chelator to the radioactive isotope lutetium-177 (¹⁷⁷Lu), enabling targeted delivery of radiation to prostate cancer cells expressing PSMA. Administered intravenously in a two-dose fractionated regimen, the approach is designed to deliver a potent and localized radiation dose while minimizing exposure to healthy organs. Compared with small-molecule radioligand therapies, the antibody-based platform may provide improved tumor selectivity, longer retention time, and enhanced internalization within cancer cells. This targeted strategy aims to increase therapeutic efficacy while limiting off-target toxicity. TLX591 is currently being evaluated in Phase III clinical development for the treatment of metastatic prostate cancer. 

CAN-2409: Candel Therapeutics

CAN-2409 is an investigational gene-mediated immunotherapy being developed for the treatment of metastatic prostate cancer (MPC). The therapy uses a replication-deficient adenoviral vector to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene directly into tumor cells. Following administration of an antiviral prodrug such as Valacyclovir, the modified tumor cells convert the drug into a toxic metabolite, leading to selective cancer cell death. This process also stimulates a systemic immune response against tumor antigens, potentially enhancing antitumor activity beyond the treated site. The drug is currently being evaluated in Phase III clinical development for metastatic prostate cancer.

ASP5541: Astellas Pharma

ASP5541 is an investigational small-molecule therapy being explored for the treatment of metastatic prostate cancer (MPC). The drug functions as a selective androgen receptor (AR) antagonist designed to inhibit androgen-mediated signaling that drives tumor growth and progression. By blocking activation of the androgen receptor, ASP5541 aims to suppress prostate cancer cell proliferation even in advanced or treatment-resistant disease. This mechanism is particularly relevant in metastatic castration-resistant prostate cancer, where AR signaling remains a key driver despite reduced testosterone levels. ASP5541 is being evaluated in Phase II stage of clinical trials for the treatment of advanced prostate cancer.

ORIC-944: ORIC Pharmaceuticals

ORIC-944 is an investigational small-molecule therapy being developed for the treatment of metastatic prostate cancer (MPC). The drug acts as a selective inhibitor of PRC2/EZH2, an epigenetic regulator that contributes to tumor progression and resistance to androgen receptor–targeted therapies. By blocking EZH2 activity, ORIC-944 aims to suppress cancer cell growth and restore sensitivity to hormonal treatments. The therapy is being explored particularly in combination with androgen receptor inhibitors for patients with metastatic castration-resistant prostate cancer (mCRPC). ORIC-944 is currently in Phase I/II stage of its clinical development for the treatment of advanced prostate cancer.

RO7656594: Roche

RO7656594 is an investigational therapeutic candidate being studied for the treatment of metastatic prostate cancer (MPC). The drug is designed to modulate immune activity within the tumor microenvironment, aiming to enhance antitumor immune responses against prostate cancer cells. By targeting immune regulatory pathways, RO7656594 may help overcome immune suppression commonly observed in advanced prostate tumors. This mechanism could potentially improve the effectiveness of immune-mediated tumor clearance in metastatic disease. RO7656594 is currently in Phase I stage of its clinical development.

Further product details are provided in the report……..

Metastatic Prostate Cancer Therapeutic Assessment

This segment of the report provides insights about the different Metastatic Prostate Cancer drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Metastatic Prostate Cancer

There are approx. 80+ key companies which are developing the therapies for Metastatic Prostate Cancer. The companies which have their Metastatic Prostate Cancer drug candidates in the most advanced stage, i.e. Phase III include, Telix Pharmaceuticals.

Metastatic Prostate Cancer Clinical Trial Phases

DelveInsight’s report covers around 85+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Metastatic Prostate Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Oral
• Intravenous
• Subcutaneous
• Parenteral 
• Topical

Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer 
• Gene therapy

Metastatic Prostate Cancer Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Metastatic Prostate Cancer Clinical Trial Activities 

The Metastatic Prostate Cancer Pipeline Report provides insights into different Metastatic Prostate Cancer Clinical Trials within Phase III, II, I, preclinical and discovery stage. It also analyses Metastatic Prostate Cancer therapeutic drugs key players involved in developing key drugs. 

Metastatic Prostate Cancer Pipeline Development Activities

The Metastatic Prostate Cancer Clinical Trial Analysis Report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Metastatic Prostate Cancer drugs.

Metastatic Prostate Cancer Report Insights

• Metastatic Prostate Cancer Pipeline Analysis
• Metastatic Prostate Cancer Therapeutic Assessment
• Metastatic Prostate Cancer Market Unmet Needs
• Impact of Metastatic Prostate Cancer Drugs

Metastatic Prostate Cancer Report Assessment

• Metastatic Prostate Cancer Pipeline Product Profiles
• Metastatic Prostate CancerTherapeutic Assessment
• Metastatic Prostate Cancer Pipeline Assessment
• Inactive Metastatic Prostate Cancer drugs assessment
• Metastatic Prostate Cancer Market Unmet Needs

Discover actionable insights into the Metastatic Prostate Cancer Market trends, epidemiology trends, and forecast through 2034 to stay ahead in emerging therapies.

Key Questions

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Metastatic Prostate Cancer drugs?
• How many Metastatic Prostate Cancer drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Metastatic Prostate Cancer?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Metastatic Prostate Cancer therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for Metastatic Prostate Cancer and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

•  Telix Pharmaceuticals 
•  Candel Therapeutics
•  Astellas Pharma
•  ORIC Pharmaceuticals
•  Roche
•  Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
•  Geode Therapeutics Inc
•  Cullgen
•  AstraZeneca
•  TYK Medicines, Inc
•  K36 Therapeutics, Inc.
•  Bristol-Myers Squibb
•  Kyntra Bio
•  ARTBIO Inc.
•  Acerand Therapeutics
•  Janux Therapeutics
•  Evopoint Biosciences Inc.
•  AbbVie
•  Arsenal Biosciences, Inc.
•  Fusion Pharmaceuticals Inc.

Key Products

•  TLX591
• CAN-2409 
•  ASP5541
•  ORIC-944
•  RO7656594
•  TQB3201
•  GT-220F
• Epigenetic Factor 
•  AZD9750
•  TYK-00540
•  KTX-2001
•  BMS-986460
•  FG-3246
•  AB001
•  ACE-232
•  JANX007
•  XNW5004
•  ABBV-969
•  AB-3028
•  FPI-2265

Explore comprehensive insights into Metastatic Prostate Cancer epidemiology trends , patient population forecasts, and growth opportunities through 2034 for strategic decision-making.